Shaping Cancer Care Today and Tomorrow: Merck to Present New Data from Rapidly Evolving Pipeline at ASCO 2017 (3)

 

Shaping Cancer Care Today and Tomorrow: Merck to Present New Data from Rapidly Evolving Pipeline at ASCO 2017 (3)

Publicado 17/05/2017 23:06:11CET

M7824, anti-PD-L1/TGF-ss trap, is an investigational potentially first-in-class bi-functional immunotherapy designed to simultaneously block two immuno-inhibitory pathways (PD-L1 and transforming growth factor beta) that are commonly used by cancer cells to evade the immune system. The aim of this investigational drug is to control tumor growth by restoring and enhancing anti-tumor immune responses. M7824 is currently in Phase I studies for solid tumors.

About Tepotinib 

Tepotinib (also known as MSC2156119J) is an investigational small-molecule inhibitor of the c-Met receptor tyrosine kinase. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tepotinib is currently under evaluation in Phase I/II trials.

About Merck  

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany holds the global rights to the "Merck" name and brand except in the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

(Logo: http://photos.prnewswire.com/prnh/20151207/293543LOGO )

Photo: http://photos.prnewswire.com/prnh/20151207/293543LOGO

CONTACT: Your Contact - Media: Gangolf Schrimpf, +49-6151-72-9591

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

La actualidad más visitada en EuropaPress logo: La actualidad más vista
Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies